25-years of experience with somatostatin receptor-based therapy in patients with small intestinal neuroendocrine tumours

#4412

Introduction: Small intestinal neuroendocrine tumours are well-differentiated and express type 2 somatostatin receptors (SSTR2). Treatment with somatostatin analogues (SSA) (octreotide or lanreotide) has been a cornerstone in controlling tumour growth for 25 years. Peptide Receptor Radionuclide Therapy (PRRT), utilising radiolabelled SSA, was introduced in our institution in May 2009 as primarily 2nd line treatment after progression on SSA. The standard PRRT regimen includes 4 cycles of PRRT (7.4 GBq 177Lu-DOTATATE every eight weeks). Re-treatment protocols remain debated.

Aim(s): To assess the median progression-free survival (mPFS) for 1) SSA, 2) 4 standard cycles of PRRT, and 3) 2 additional PRRT cycles in patients with a good initial PRRT response.

Materials and methods: A retrospective, single-centre study, including consecutive patients who initiated treatment with SSTR based therapy between 2000 and 2020.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Oturai P, Langer S, Møller S, Hansen C,

Keywords: SSA, PRRT, small intestinal NET,